The U.S. Department of Health and Human Services has partnered with Regeneron Pharmaceuticals Inc to develop a treatment for the coronavirus whose outbreak in China has killed hundreds of people in China alone.

The drugmaker collaboration with the U.S. Department of Health and Human Services is the latest to join the race to develop a therapy. It also expands on a previous 2017 agreement to develop treatments for pathogens that pose significant risk to the public.

Regeneron had partnered with an HHS unit to develop treatments for Ebola in 2017.

“Regeneron will now use the same technology that was used to develop an experimental drug to treat Ebola in the Democratic Republic of Congo”, said the U.S. agency.

The drugmaker will focus on developing infection-fighting proteins known as monoclonal antibodies.

Other drugmakers who are in the race to create a treatment for coronavirus includes Gilead Sciences Inc, Moderna Inc, and Johnson & Johnson.